Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Profit After Tax (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Profit After Tax over the past 9 years, most recently at -$8.0 million for Q4 2023.

  • For Q4 2023, Profit After Tax rose 26.26% year-over-year to -$8.0 million; the TTM value through Dec 2023 reached -$44.6 million, down 5.33%, while the annual FY2024 figure was -$40.2 million, 9.85% up from the prior year.
  • Profit After Tax for Q4 2023 was -$8.0 million at Corbus Pharmaceuticals Holdings, up from -$10.1 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $2.2 million in Q2 2019 and troughed at -$38.1 million in Q2 2020.
  • A 5-year average of -$15.8 million and a median of -$12.1 million in 2022 define the central range for Profit After Tax.
  • Biggest five-year swings in Profit After Tax: soared 117.84% in 2019 and later tumbled 1870.16% in 2020.
  • Year by year, Profit After Tax stood at -$26.6 million in 2019, then soared by 67.6% to -$8.6 million in 2020, then decreased by 19.15% to -$10.3 million in 2021, then decreased by 6.03% to -$10.9 million in 2022, then rose by 26.26% to -$8.0 million in 2023.
  • Business Quant data shows Profit After Tax for CRBP at -$8.0 million in Q4 2023, -$10.1 million in Q3 2023, and -$8.8 million in Q2 2023.